Abstract
The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4–ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors containing this genetic abnormality. In this mini review, we discuss the existing data on crizotinib as well as ongoing trials involving this medication. A brief overview of the known resistance mechanisms to crizotinib will also be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC.
Highlights
Treatment for non-small cell lung cancer (NSCLC) has historically consisted of cytotoxic chemotherapy
Multiple phase III randomized trials are in progress to assess the efficacy of crizotinib as first-line chemotherapy
Given the positive response rates with crizotinib, multiple phase III trials are currently in progress to address the efficacy of crizotinib as first-line therapy
Summary
Treatment for non-small cell lung cancer (NSCLC) has historically consisted of cytotoxic chemotherapy. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer A brief overview of the known resistance mechanisms to crizotinib will be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
